Research progress of tadalafil in the treatment of erectile dysfunction
10.13263/j.cnki.nja.2025.10.012
- VernacularTitle:他达拉非治疗勃起功能障碍临床应用研究进展
- Author:
Junjie WU
1
;
Mingwei ZHAN
;
Xuejun SHANG
Author Information
1. 南京中医药大学金陵临床医学院泌尿外科,南京 210002
- Publication Type:Journal Article
- Keywords:
erectile dysfunction;
comorbidity;
endothelial function;
long-acting phosphodiesterase type 5 inhibitor;
tadalafil
- From:
National Journal of Andrology
2025;31(10):942-950
- CountryChina
- Language:Chinese
-
Abstract:
Erectile dysfunction(ED)is a common sexual dysfunction in adult males.With the accelerated pace of modern life and lifestyle changes,the prevalence of ED and its associated comorbidities have been steadily rising.Problems such as premature ejaculation,hypertension,hyperlipidemia,diabetes,prostate diseases,and infertility all interact with and aggravate ED,thereby endangering the overall health of men.Phosphodiesterase type 5 inhibitors(PDE5i)is the first-line pharmacotherapy for ED.Tadalafil,currently the only long-acting PDE5i approved for clinical use,has received mar-keting authorization in China for the treatment of ED since 2005.In 2013,the once-a-day continuous regimen was intro-duced as a novel treatment paradigm.And the indication was expanded to ED coexisting with benign prostatic hyperplasia in 2019.Accumulating clinical experience and evidence-based data consistently demonstrate its efficacy and safety across ED and ED-related comorbidities.This review summarizes the pharmacological profile of tadalafil and the latest clinical evi-dence on the management of ED and ED-related comorbidities,aiming to provide a reference for clinical practice.
